Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis

Exclusion Criteria

• •Patients who have a diagnosis of any other type of inflammatory arthritis.
• •Patients who have a secondary, non-inflammatory type of arthritis.
• •Patients who have used with MTX, reflunomide, or any other biologics prior to the start of study drug administration.
• •Patients who have NYHA (New York Heart Association) Class III or IV congestive heart failure
• •Patients who currently have, or who have a history of, tuberculosis.
• •Patients who have a high risk of infection (with a current infectious disease, a chronic infectious disease, a history of serious infectious disease)
• •Patients who currently have, or have a history of, malignant tumor
• •Female patients who are breastfeeding or pregnant, who are of childbearing potential